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Abstract
Background Liver resection produces excellent long-term survival for patients with colorectal liver metastases but is
associated with significant morbidity and mortality from ischaemia reperfusion injury (IRI). Remote ischaemic
preconditioning (RIPC) can reduce the effect of IRI. This pilot randomised controlled trial evaluated RIPC in patients
undergoing major hepatectomy at the Royal Free Hospital, London.
Methods Sixteen patients were randomised to RIPC or sham control. RIPC was induced through three 10-min cycles
of alternate ischaemia and reperfusion to the leg. At baseline and immediately post-resection, transaminases and
indocyanine green (ICG) clearance were measured.
Findings The RIPC group had lower ALT and AST levels immediately post-resection (ALT: 43% lower 497 ± 165
vs 889 ± 170 IU/L; p = 0.019 AST: 54% lower 408 ± 166 vs 836 ± 167 IU/L; p = 0.001) and at 24 h (ALT: 41%
lower 412 ± 144 vs 698 ± 137 IU/L; p = 0.026 AST: 50% lower 316 ± 116 vs 668 ± 115 IU/L; p = 0.02). ICG
clearance was reduced in controls versus RIPC immediately after resection (ICG-PDR: 11.1 ± 1.1 vs 16.5 ± 1.4%/
min; p = 0.035).
Conclusions This pilot study shows that RIPC has potential to reduce liver injury following hepatectomy justifying a
prospective RCT powered to demonstrate clinical benefits.
Introduction
Liver resection for colorectal metastasis is the gold stan-
dard treatment and has improved survival in patients with
colorectal liver metastasis [1, 2]. Warm ischaemia reper-
fusion injury (IRI) to the liver occurs during major liver
resections with mobilisation and retraction of the liver and
with the use of temporary portal inflow occlusion (Pringle
manoeuvre) [3]. Even in the absence of inflow occlusion,
oxygenation of the liver tissue is significantly reduced
during mobilisation prior to parenchymal transection [4],
resulting in repetitive warm IR injury and significant hep-
atocyte death prior to parenchymal transection and inflow
occlusion [5, 6]. Livers with fibrosis, steatosis or following
neo-adjuvant chemotherapy [7] are more susceptible to this
warm IR injury. The mean age of patients undergoing liver
resection is 60 years [8], and more patients are undergoing
neo-adjuvant chemotherapy. As such, strategies to ame-
liorate IRI are a key clinical concern especially in this
group of patients.
Various strategies to reduce IRI to the liver have been
described including ischaemic preconditioning (IPC), which
may be applied directly or remotely. Ischaemic
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preconditioning reduces the adverse effects of IRI through
previous exposure to a brief period(s) of vascular occlusion.
Direct IPC has been shown to reduce IRI in experimental
models of warm hepatic IRI [9] and in patients undergoing
major liver resections [10, 11]. However, experimental
studies have shown that direct IPC through clamping of the
portal inflow vessels may impair liver regeneration [12, 13]
and in a multivariate analysis of patients undergoing liver
resection, this was found to be an independent predictor for
increased post-operative morbidity [14].
Novel methods of preconditioning without direct stress to
the liver include remote ischaemic preconditioning (RIPC)
[15]. In RIPC, a remote organ is preconditioned prior to
ischaemia of the target organ, and in experimental studies, this
has been shown to reduce IRI to the myocardium [16], the
liver [17, 18] and other organs [15]. The beneficial effect of
RIPC in reducing IRI was first demonstrated in paediatric
patients undergoing cardiopulmonary bypass [19]. Results
from following clinical trials and meta-analyses in cardiac
and vascular surgery have been varied [16, 20–26]. It is
unclear why some trials have shown evidence of protection
while others have not. This may reflect underlying comor-
bidities, different conditioning protocols or variability in the
potential for a target organ to be preconditioned. As the
mechanism by which RIPC provides protection remains
unknown, it is difficult to understand what is the reason for
these differing results.
We have previously shown that RIPC can reduce liver IRI
in an experimental model [17]. This current trial is a proof of
concept study to determine whether RIPC reduces IRI in
patients undergoing major liver resectional surgery and to
help determine potential end points for a subsequent trial to
determine the risks and benefits of RIPC in patients under-
going major liver resection for colorectal liver metastases.
In this study, in addition to measuring biochemical
parameters of hepatocellular injury, indocyanine green
(ICG) clearance from the liver and ICG plasma disap-
pearance rate (ICG-PDR) has been measured which pro-
vide reliable early indicators of post-operative liver
function [27]. To predict liver injury after hepatectomy and
to assess functional hepatic reserve, static measures of liver
function such as transaminases [28] have limited reliability.
Dynamic tests using ICG clearance and lidocaine meta-
bolism are superior with ICG having the advantage of
being measured non-invasively [29]. There is a close cor-
relation between the ICG-PDR and ICG-retention rates
measured non-invasively and their corresponding values
calculated by conventional ICG methods [30].
Hypothesis
The hypothesis was that RIPC would be safe and feasible
in patients undergoing liver resection surgery and that
RIPC would result in evidence of a reduction in peri-op-
erative liver injury.
Materials and methods
A single-centre blind prospective randomised controlled
trial was performed at the Royal Free Hospital, between
April 2005 and April 2007, following approval by the local
NHS ethical board (54,561,358). The trial involved ran-
domisation of patients undergoing major liver resection (3
segments or more) for colorectal liver metastasis and was
carried out in conjunction with a similar trial in liver
transplant recipients. It was registered with ClinicalTri-
als.gov: Number NCT00796588.
Patients above the age of 18 being considered for major
liver resection for colorectal liver metastasis under 3 sur-
geons were enrolled in the study. Exclusion criteria
included: the absence of written informed consent,
peripheral vascular disease, blood disorders, e.g. sickle cell
disease, localised limb infections, pregnancy, severe co-
morbid disease, uncontrolled diabetes and sepsis.
Twenty-two patients were assessed for eligibility fol-
lowing which 6 were excluded and 16 were randomised
into a control and a RIPC group. For randomisation,
computer-generated random numbers were generated and
stored in sealed envelopes which were opened following
induction of anaesthesia. Patients were blinded to the
intervention (RIPC or sham), but the surgeon was not.
The preconditioning stimulus
In the control group, a sham consisted of a pneumatic
tourniquet being placed on the right upper thigh without
being inflated. In the RIPC group, following general
anaesthesia but before the abdominal incision, the lower
limb was covered with two layers of stockinette and ele-
vated to 45 for 3 min. A wide pneumatic tourniquet was
applied to the right upper thigh in accordance with safe and
recommended practices by the Association of Peri-opera-
tive Registered Nurses (AORN) [31]. To induce RIPC, the
tourniquet was inflated to twice the measured systolic
arterial pressure for 10 min and then deflated for 10 min to
reperfuse the leg. This was repeated twice and completed
prior to commencing the operation (Fig. 1).
The surgical procedure
Liver resection was performed through a hockey stick
incision. Inflow vessels on the side of the resection were
divided extra-parenchymally. Portal vascular inflow
occlusion (Pringle manoeuvre) was not required in any of
the patients in the study. Liver transection was performed
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using an ultrasonic dissector in all cases. All patients
received antibiotic prophylaxis and post-operatively a daily
subcutaneous injection of low molecular weight heparin as
thrombo-prophylaxis.
Data collection and measurements
Complications
During the preconditioning stimulus, patient’s haemody-
namics were continually monitored. Patients were clini-
cally examined post-operatively for evidence of deep vein
thrombosis (DVT) or pulmonary embolus (PE) formation
and limb paraesthesia or pain. Doppler ultrasound or CT
pulmonary angiogram was requested if there was clinical
suspicion of embolus formation.
Blood measurements
In both groups, 35 mls of peripheral blood was collected at
the following time intervals: baseline (following induction
of anaesthesia), at the end of the liver resection, and 24 h
post-operatively. Whole blood samples were collected
from the arterial line in precooled tubes for the measure-
ment of serum transaminases, serum bilirubin, urea and
electrolytes. Measurements were made using an automated
clinical chemistry analyser (Hitachi 747, Roche Diagnos-
tics Ltd., Sussex, UK).
Indocyanine green (ICG) pulse densitometry
ICG is a fluorescent dye eliminated exclusively by the
liver, and its elimination rate is used to evaluate global
liver function. A bolus of 50 mg ICG (dry powder) [Limon,
Pulsion, Munich, Germany] was dissolved in the supplied
solvent giving a concentration of 5 mg dye/ml solvent.
This was injected slowly intravenously in a dose of 0.5 mg/
kg through the central line. Both absorption and emission
spectrum of ICG are in the near-infrared range, and its
concentration can be quantified by actual absorbance either
invasively with a fibre-optic catheter or non-invasively
through the skin [32]. In this trial, the blood concentration
of ICG was measured non-invasively via an optical probe
attached to the patient’s finger and connected to a trans-
cutaneous pulse densitometry monitor (Limon, Pulsion
Medical Systems AG, Munich, Germany). Measurements
were made at baseline and immediately following com-
pletion of liver resection and were recorded as plasma
disappearance rate of ICG [ICG-PDR (%/min)] and ICG
retention rate after 15 min (R 15%).
Histological examination
The resected liver specimen was fixed in 10% formalin.
Tissues were embedded in paraffin and stained with
haematoxylin–eosin for histological examination. Accord-
ing to the Royal College of Pathologists guidelines, the
resected specimen was evaluated for resection margins,
Fig. 1 Trial protocol
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nature, distribution and differentiation of the tumour. The
normal liver parenchyma was examined for significant
signs of IRI, steatosis and fibrosis. Histological evidence of
IRI included portal tract inflammation with neutrophil
infiltration, hepatocyte ballooning or apoptosis/necrosis
and disruption of the trabecular architecture around the
central lobar vein. The reporting pathologist was blinded to
the trial arm that the patient was allocated to.
Statistical analysis and power calculations
Although power calculations are not deemed necessary for
a pilot feasibility trial, previous studies in direct IPC have
achieved a 50% reduction in serum transaminases in
comparison with the control group at 24 h post-reperfusion
[10, 33]. To demonstrate a benefit of RIPC in reducing
liver injury as indicated by a reduction in serum transam-
inases with a statistical significance (p\ 0.05), a power of
80% (two-tailed test of proportions), an a-error of 0.05 and
a b-error of 0.00, it was calculated that a sample size of at
least 8 patients per group was required. Distribution of data
was analysed by Shapiro–Wilk test and Q–Q plots. Con-
tinuous data were expressed as mean (±SD), and com-
parisons between groups were tested by unpaired Student’s
t test as appropriate. Dichotomous data were presented as a
proportion of the whole and comparisons between groups
were tested by Chi-squared tests. A p value of\0.05 was
considered significant, and analysis was by intention to
treat.
Results
Twenty-two patients undergoing liver resection surgery for
colorectal liver metastases were approached with 1 patient
not wishing to participate in the trial. Five patients were
further excluded. Two patients were found to have minor
peripheral vascular disease. Three patients who were
expected to undergo a major resection underwent a multi-
ple wedge resections and were excluded prior to ran-
domisation. Of the remaining 16 patients, 8 were
randomised to the control group and 8 were randomised to
the intervention (RIPC) group (Fig. 2). Both groups were
well matched at baseline including incidence of pre-oper-
ative chemotherapy and degree of steatosis (Table 1).
Safety and feasibility
Seventy-three percentage of patients approached were
recruited to the trial. All patients randomised to the RIPC
group successfully underwent RIPC, and there was a 0%
drop out rate post-randomisation.
No patients experienced haemodynamic instability dur-
ing cuff inflation.
On clinical examination, there was no evidence of DVT
or PE formation. No patient required a Doppler USS or
CTPA. No patient complained of pain or paraesthesia post-
operatively.
Clinical outcomes
There were no deaths in either group, and no patient suf-
fered from post-operative liver failure. There was a higher
incidence of both wound infections (2 vs 1, p = 0.38) and
basal atelectasis (4 vs 3, p = 0.62) in the control group
although neither of these were significant. One patient in
the RIPC group developed a post-operative pneumonia,
and one patient in the control group developed a post-
operative intra-abdominal collection that required radio-
logical drainage. Patients who underwent RIPC spent on
average longer in ITU post-operatively although this was
not significant (2 vs 1.5 days, p = 0.46).
Serum transaminases
In both groups, serum ALT levels at the end of the resec-
tion and at 24 h post-resection were significantly raised vs
baseline (Fig. 3a). At the end of resection, serum ALT
levels were 43% lower in the RIPC group compared to the
control group (497 ± 165 vs 889 ± 170 IU/L; p = 0.019).
At 24 h post-resection, ALT levels were 41% lower in the
RIPC group than in the control group (412 ± 144 vs
698 ± 137 IU/L; p = 0.026).
The pattern was similar for the changes in AST. At the
end of resection, serum AST levels were 54% lower in the
RIPC group compared with the control group (408 ± 166
vs 836 ± 167 IU/L; p = 0.001). At 24 h post-resection,
serum AST levels were 50% lower in the RIPC group
compared to the control group (316 ± 116 vs
668 ± 115 IU/L; p = 0.02) (Fig. 3b). There were no sig-
nificant differences in mean serum bilirubin levels between
the two groups at the measured time points.
ICG measurements
The plasma disappearance rate of ICG (ICG-PDR) at
baseline in the two groups was similar (control 22.6 ± 1.9
vs RIPC 21.5 ± 1.8%/min). After liver resection, there was
a significantly higher ICG clearance in the RIPC group
(control 11.1 ± 1.1 vs RIPC 16.5 ± 1.4%/min; p = 0.035)
(Fig. 4a). Similarly the ICG retention at 15 min [R 15 (%)]
at baseline in the two groups was similar (control 6.5 ± 1.2
vs RIPC 7.1 ± 1.6%), whereas after liver resection there
was a significantly reduced retention of ICG in the RIPC
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group (control 17.5 ± 1.3 vs RIPC 12.8 ± 1.6%;
p = 0.041) (Fig. 4b).
Histological findings
In both groups, histology of the liver from the resected
specimens was similar to minimal steatosis. There was no
pathological evidence of IRI seen.
Discussion
This pilot feasibility study has shown that RIPC is safe and
feasible in patients undergoing liver resection for colorectal
liver metastases. Although the trial was not powered to
demonstrate improved clinical outcome, a reduction in
liver injury as determined by a significant reduction in
post-operative serum transaminases and significantly
increased ICG clearance was demonstrated in patients
undergoing RIPC prior to liver resection.
Liver resection is regarded as the gold standard of treat-
ment for resectable colorectal metastases [1]. The success of
the surgery has led to patients requiring extensive
parenchymal resections being offered hepatic resection with
the risk of post-operative hepatic insufficiency secondary to
insufficient residual liver volume. Following surgical
resection morbidity can be up to 36%. Besides the extent of
the resection, the finding at surgery of liver steatosis and
fibrosis is additional important risk factors for post-operative
hepatic insufficiency [34] and impaired liver regeneration
[35] due to the increased susceptibility to warm IRI [36, 37].
Patients with colorectal metastasis are usually elder (median
age 60 years). In experimental models, aged livers have a
greater susceptibility to minor degrees of warm IRI [38].
This study has shown that RIPC reduces markers of
hepatocellular injury following liver mobilisation in
patients undergoing major liver resections and increases
the ICG clearance, an important indicator of liver viability
[27]. Studies investigating the release of markers of liver
parenchymal damage (transaminases and glutathione
Assessed for eligibility (n=22)
Excluded  (n=6)
♦ Not meeting inclusion criteria (minor 
resections) (n=3)
♦ Declined to participate (n=1)
♦ Other reasons (prior history of 
venous embolism) (n=2)
Analysed  (n=8)
♦ Excluded from analysis (give reasons) (n=0)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=0)
Allocated to intervention (n=8)
♦ Received allocated intervention (n=8)
♦ Did not receive allocated intervention (give 
reasons) (n=0)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=0)
Allocated to intervention (n=8)
♦ Received allocated intervention (n=8)
♦ Did not receive allocated intervention (give 
reasons) (n=0)
Analysed  (n=8)
♦ Excluded from analysis (give reasons) (n=0)
Allocation
Analysis
Follow-Up
Randomized (n=16)
Enrollment
Fig. 2 Randomisation according to the CONSORT guidelines
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S-transferase) at different stages during and after major
liver resection have shown that a significant reduction in
hepatic oxygenation occurs during mobilisation of the liver
[4] and that markers of parenchymal injury and hepatocyte
cell death are significantly raised following mobilisation in
the absence of inflow occlusion [5, 6]. This is in keeping
with the results from this study which has demonstrated a
significant increase in serum transaminase levels in the
absence of inflow occlusion and demonstrates that RIPC
can protect the liver from this parenchymal injury. This is
important as the potential benefits RIPC can be provided
more globally rather than only in patients undergoing
inflow occlusion.
No patients in this trial had steatosis or fibrosis of the
liver; however, 5 patients had undergone neo-adjuvant
chemotherapy. If these results can be reproduced in a more
extensive trial including patients with risk factors for post-
operative liver insufficiency (elderly, prolonged
chemotherapy, steatosis, reduced residual liver volume),
this may translate into a reduction in the morbidity and
mortality associated with liver resection.
The two groups in the trial were well matched for
baseline clinical characteristics and indications for hepa-
tectomy. Following major liver resection, serum transam-
inases increase, peak between 24 and 36 h and return to
normal levels within 3–5 days [39]. The severity of IRI is
Table 1 Demographic data
Control group RIPC group
Age (years) 66–74 58–77
Sex ratio (M:F) 6:2 7:1
BMI (kg/m2) 17–34 22–34
Operative procedure
Right hepatectomy 6 5
Extended right hepatectomy 2 2
Left hepatectomy 0 1
Neo-adjuvant chemotherapy 3 2
Duration of operation (h) 6.25 (4.5–8) 6.15 (4.7–7.6)
Intra-operative parameters
Central venous pressure (mmHg) 10 (8–12) 9 (7–14)
Mean arterial blood pressure (mmHg) 69 (60–77) 70 (65–80)
Blood transfusion (mls) 300 (0–500) 350 (0–750)
Fig. 3 a In both groups, serum
ALT levels at the end of
resection and 24 h post-
resection were raised versus
baseline. At the end of
resection, ALT levels were 43%
lower in the RIPC group versus
control (p = 0.019) and at 24 h
was 41% lower versus control
(p = 0.026). b In both groups,
serum AST levels at the end of
resection and at 24 h post-
resection were raised versus
baseline. At the end of
resection, serum AST levels
were 54% lower in the RIPC
group versus control
(p = 0.001). At 24 h post-
resection, serum AST levels
were 50% lower in the RIPC
group versus control (p = 0.02)
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reflected by a rise in serum transaminase levels. In this
study in all patients in the two groups, both serum AST and
ALT levels increased at the end of the liver resection,
peaked at 24 h and returned to normal in 5 days. RIPC
produced a significant reduction in serum transaminases at
the end of surgery and at 24 h post-reperfusion. There was
no difference between RIPC and sham groups at 5 days.
Direct IPC of the liver in patients undergoing liver resec-
tion [10] and liver transplantation [33] also results in a
reduction in serum transaminases. However, in experi-
mental studies direct IPC has been shown to impair liver
regeneration [12, 13] and is associated with a higher risk of
post-operative morbidity in patients undergoing major
hepatectomy [14]. Hence, in steatotic and small remnant
livers even this short duration of direct stress to the liver
may be detrimental. This stress can be avoided through
remote preconditioning. A limitation of this trial, however,
is that RIPC has not been compared against direct IPC of
the liver; however, in such a small pilot trial there was
insufficient numbers to perform this. Furthermore, the
primary aim of this study was to check for feasibility and
safety of limb RIPC. Future large RCTs should incorporate
a direct IPC arm to allow for a comparison between IPC
and RIPC.
Indocyanine green (ICG) is eliminated by the liver lar-
gely unchanged into bile and does not undergo entero-
hepatic recirculation. Elimination is dependent on several
factors including hepatic blood flow, hepatocellular uptake
and biliary excretion. Hence, the rate of disappearance
from the plasma [ICG-PDR (%/min)] and its percentage
retention in the liver at 15 min [R 15 (%)] is a dynamic
measure of liver function describing the functional status of
the liver at the time of assessment [27]. ICG retention of
[15% after 15 min of a bolus injection of ICG is an
indicator of significant liver dysfunction and a predictor of
reduced patient survival following major liver resections
[40]. Measurement of ICG-PDR is more sensitive than
serum enzyme tests for assessing liver dysfunction and
predicting outcome [41]. In liver transplantation, ICG-PDR
measured immediately after liver reperfusion is useful for
early diagnosis of primary graft dysfunction and allografts
with ICG-PDR of \15%/min have borderline function
[42]. Levels below 5%/min are associated with a high risk
of graft failure [27]. In this trial, RIPC improved liver
function as demonstrated by an increased ICG plasma
clearance and a reduced ICG retention when compared
with the control group. Although a reduction in liver injury
and improved liver function following RIPC has been
identified in this study by reduced transaminases and
increased ICG clearance, further sensitive markers of liver
injury could be incorporated into future trials including
liver fatty acid binding proteins and glutathione S-trans-
ferase to further clarify the protection gained by RIPC.
A limitation of this study is that it has not investigated
for potential mechanisms of the protection of RIPC. Liver
injury propagates an inflammatory response [5], and it has
been shown in animal models that mice lacking CD4? T
cells are protected from warm hepatic IRI [43]. Analysis of
serum cytokines (IL-6, IFNc and TNFa) during and post-
liver resection could be incorporated into future studies to
Fig. 4 a ICG-PDR of\15%/
min indicates borderline liver
function. ICG-PDR at baseline
in the two groups was not
different, but immediately after
liver resection there was a
significant difference between
the two groups (p = 0.035).
b ICG retention of[15% after
15 min [ICG-R 15 (%)] after
ICG injection is an indicator of
severe liver dysfunction. ICG-R
15 (%) at baseline in the two
groups were the same, but
immediately after liver resection
there was a significant
difference between the two
groups (p = 0.041)
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measure the inflammatory response and identify the effect
of RIPC on this mechanism of injury.
This study has demonstrated the safety of inducing
RIPC using a pneumatic limb tourniquet. A standard
orthopaedic tourniquet was utilised in the trial as would be
used to perform limb surgery in a bloodless field. Tourni-
quet-associated complications including pain, paraesthesia,
pressure changes and haemodynamic disturbances usually
occur continuous inflation for more than half an hour [44]
and were not observed at any stage during this trial.
Standard safety and utilisation guidelines would appear to
be adequate to guide the use of a pneumatic tourniquet for
producing remote preconditioning.
The benefit of RIPC has not been previously demon-
strated in liver resection surgery. Clinical trials in cardio-
vascular surgery have shown that RIPC may reduce
myocardial injury. The benefit of RIPC was first shown in
children undergoing cardiac surgery [19]. Subsequently,
RIPC was shown to reduce myocardial injury in patients
undergoing coronary artery bypass surgery [16, 22] and the
incidence of peri-operative infarcts in those undergoing
aortic surgery [21]. Two large recent trials, however, have
failed to demonstrated clinical benefit following RIPC in
the setting of cardiac surgery [25, 26]. What is clear from
these trials is that differing protocols for the precondi-
tioning stimulus have been used with varying numbers of
cycles (2 vs 4) and different methods of vascular occlusion
(direct vascular clamping vs limb tourniquet). It has pre-
viously been shown in animal models that clamping of the
femoral pedicle was as efficacious as a limb tourniquet in
ameliorating IR injury [45]. What has not been elucidated
is the number and length of cycles that are required to
effectively precondition humans. In trials of IPC of donors
during liver transplantation, 5 min of portal inflow occlu-
sion was found to be insufficient to reduce IR injury [46]
while 10 min of portal inflow occlusion was shown to
reduce post-operative transaminase levels [33]. Three
cycles of 5 min have been sufficient to ameliorate IR injury
in small animal models [15], but there is no consensus as to
what stimulus is required to adequately precondition
humans. In this trial, we performed 3 by 10-min cycles.
This longer period of limb ischaemia may explain why
RIPC has ameliorated IR injury in this trial compared to
others which have used 5-min cycles [25, 26]. It is difficult,
however, to draw direct conclusions as the target organ to
protect and the limb used (upper vs lower) were different.
A further trial comparing 5-min cycles against 10-min
cycles is necessary to answer this question.
This clinical study was designed as a pilot feasibility
RCT to determine whether patients would be willing to be
recruited to a limb preconditioning study with the possi-
bility that they would be randomised to a sham and whether
there were risks involved in limb preconditioning using a
pneumatic tourniquet. A cohort study using a historical
control group would have allowed a comparison between a
greater number of patients but would not provide the data
on recruitment to help design a future large RCT and would
introduce bias due to advances in parenchymal transection
techniques and intra-operative blood loss management.
Secondary end points which could be used to power a
future clinical trial aimed at evaluating the efficacy of
RIPC in patients undergoing major liver resections were
measured. We have demonstrated that the procedure is
acceptable to patients and have found no evidence of
complications following RIPC. Surprisingly for a pilot
study, we have demonstrated a statistically significant
benefit to RIPC in terms of lower post-operative transam-
inases and improved ICG clearance. These pilot data would
justify a prospective clinical trial determining whether
RIPC can improve clinical outcomes in major liver surgery.
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